Guided Therapeutics Receives Order for 7 LuViva® Advanced Cervical Scans and 4,000 Disposable Cervical Guides for Indonesia

NORCROSS, Ga.–(BUSINESS WIRE)–Guided Therapeutics, Inc. (OTCQB: GTHP), developer of the LuViva®Advanced
Cervical Scan, a non-invasive device used to detect cervical disease
instantly and at the point of care, today announced it has received an
order for seven additional LuViva® Advanced Cervical Scans and 4,000
disposable Cervical Guides for Indonesia.
The order follows a recent recommendation that LuViva be included as an
alternative to the Pap test at the 22nd Annual Scientific Meeting of the
Society of Obstetricians and Gynecologists of Indonesia. The order
brings to 14 the number of LuVivas and almost 7,000 the number of
disposable Cervical Guides sold to Indonesia.
“We believe that the recommendation to include LuViva as an alternative
to the Pap test will have a very positive effect for the product in
Indonesia, the fourth most populous market in the world,” said Gene
Cartwright, CEO and President of Guided Therapeutics, Inc. “Cervical
cancer is the second most common malignancy among women of Indonesia
with an incidence rate of about 17 in 100,000. In Indonesia, 70% of
cervical cancer cases diagnosed are in the advanced stage, there is a
clear unmet need to increase screening to detect cervical disease before
it develops into cancer.”
In Indonesia, more than 93 million women are at risk of developing
cervical cancer. Less than 25% of women aged 30 to 50 are screened for
cervical cancer in Indonesia with the primary method of visual
inspection with acetic acid.
There are about 2.6 billion women aged 15 years and older who are at
risk of developing cervical cancer worldwide. The world market for
cervical cancer screening and diagnostics, as currently practiced using
cytology (Pap test) for primary screening, is estimated at $6 billion
and is projected to grow to almost $9 billion by 2020.
About LuViva^® Advanced Cervical Scan
LuViva is a technologically advanced diagnostic device that scans the
cervix with light and uses spectroscopy to measure how light interacts
with the cervical tissue. Spectroscopy identifies chemical and
structural indicators of precancer that may be below the surface of the
cervix or misdiagnosed as benign. This technique is called biophotonics.
Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory
analysis or a tissue sample, and is designed to provide results
immediately, which may result in eliminating costly, painful and
unnecessary additional testing. LuViva is intended for use with women
who have undergone initial screening and are called back for follow up
with a colposcopy examination, which in many cases, involves taking a
biopsy of the cervix. It has also been used in clinical studies in
Turkey and Nigeria as a means to screen women for cervical cancer where
the availability of infrastructure necessary for Pap and HPV testing is
restricted. The device is used in conjunction with the LuViva® Cervical
Guide single-use patient interface and calibration disposable.
About Guided Therapeutics
Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and
painless testing platform based on its patented biophotonic technology
that utilizes light for the early detection of disease at the cellular
level. The Company’s first product is the LuViva®Advanced
Cervical Scan, a non-invasive device used to detect cervical disease
instantly and at the point of care. In a multi-center clinical trial
with women at risk for cervical disease, the technology was able to
detect cervical cancer up to two years earlier than conventional
modalities, according to published reports. For more information, visit: www.guidedinc.com.
The Guided Therapeutics LuViva^® Advanced
Cervical Scan is an investigational device and is limited by federal law
to investigational use in the U.S. LuViva, the wave logo and “Early
detection, better outcomes” are registered trademarks owned by Guided
Therapeutics, Inc.
Forward-Looking Statements Disclaimer: A number of the matters and
subject areas discussed in this news release that are not historical or
current facts deal with potential future circumstances and developments.
The discussion of such matters and subject areas is qualified by the
inherent risks and uncertainties surrounding future expectations
generally and also may materially differ from Guided Therapeutics’
actual future experience involving any of or more of such matters and
subject areas. Such risks and uncertainties include those related to the
early stage of commercialization of products, the uncertainty of market
acceptance of products, the uncertainty of development or effectiveness
of distribution channels, the intense competition in the medical device
industry, the sufficiency of capital raised in prior financings and the
ability to realize their expected benefits, the uncertainty of future
capital to develop products or continue as a going concern, the
uncertainty of regulatory approval of products, and the dependence on
licensed intellectual property, as well as those that are more fully
described from time to time under the heading “Risk Factors” in Guided
Therapeutics’ reports filed with the SEC, including Guided Therapeutics’
Annual Report on Form 10-K for the fiscal year ended December 31, 2015
and subsequent filings.